XACDURO is a new FDA-approved treatment used to fight against HABP/VABP infections caused by isolates of Acinetobacter baumannii-calcoaceticus complex, which can include those resistant to carbapenems (CRAB).In the U.S.,
Las Vegas Sands (NYSE:LVS) reported quarterly losses of $(0.34) per share which missed the analyst consensus estimate of $(0.27) by 25.93 percent. This is a 30.77 percent decrease over losses of $(0.26) per share from